Shingles Vaccine Market Size, Share, Trends, Growth, and Regional Forecast, 2025 to 2032

The global shingles vaccine market is valued at US$5.7 billion in 2025 and is projected to reach US$14.1 billion by 2032, growing at a CAGR of 13.7% from 2025 to 2032. Increasing awareness of herpes zoster and its complications, particularly postherpetic neuralgia, among the aging population drives the need for shingles vaccines.

Recombinant vaccines, such as Shingrix, dominate because of their higher efficacy and suitability for immunocompromised adults, surpassing traditional live-attenuated vaccines. Rising prevalence of chronic diseases, government initiatives to promote adult immunization, and growing demand for safe, effective, and accessible vaccines are expected to sustain market momentum over the forecast period.

• The shingles vaccine market is experiencing steady growth, driven by increasing awareness of herpes zoster and its complications, especially postherpetic neuralgia.
• Live-attenuated vaccines, such as Zostavax, still hold a share in certain regions but are declining in popularity due to reduced efficacy in older adults and immunocompromised patients.
• Key drivers include the aging global population, rising prevalence of chronic conditions, increased awareness of shingles complications, and expanding government immunization campaigns.
• Opportunities lie in emerging markets, immunocompromised patient segments, and next-generation recombinant vaccines.

Driver - Increasing Incidence of Immunocompromised Patients

The rising prevalence of immunocompromised individuals is driving global demand for shingles vaccines. Patients undergoing organ transplants, chemotherapy, or long-term corticosteroid therapy have weakened immune systems, making them highly vulnerable to herpes zoster infection and its severe complications, including postherpetic neuralgia.

Awareness among healthcare providers about the elevated risk in these populations has prompted proactive vaccination recommendations. As a result, healthcare facilities increasingly prioritize shingles vaccination as a preventive measure for immunocompromised adults. This trend is especially prominent in developed markets with advanced healthcare infrastructure and targeted adult immunization programs, supporting sustained market growth.

Restraints - Side Effects and Safety Concerns

Shingles vaccines, particularly recombinant formulations such as Shingrix, are generally safe and effective, but side effects remain a key concern affecting patient adoption. Common reactions include pain, redness, or swelling at the injection site, mild fever, fatigue, headache, and muscle aches, usually resolving within a few days.

While these are temporary, they can cause discomfort and deter some patients, especially older adults. Rare but more serious reactions, such as severe allergic responses or neurological events, though extremely uncommon, further contribute to hesitancy among risk-averse individuals. Educating patients on the safety profile is essential to increase confidence and uptake.

Opportunity - Multi-Dose and Long-Lasting Formulations

The development of multi-dose or long-lasting shingles vaccines represents a significant opportunity to transform patient adherence and market dynamics. Traditional two-dose regimens often face challenges, including missed follow-ups, logistical complexities, and increased healthcare visits, which can limit real-world effectiveness.

By introducing vaccines that offer prolonged immunity with fewer doses or even a single-dose formulation, manufacturers can simplify vaccination schedules, improve completion rates, and enhance overall patient convenience. Such innovations also reduce storage and distribution burdens for healthcare providers, particularly in large-scale immunization programs.

Moreover, long-acting formulations provide differentiation in a competitive market, enabling premium positioning and greater adoption across both private and public healthcare segments, especially among aging populations seeking reliable, hassle-free protection.

By Product Type Insights

Shingrix dominates the shingles vaccine market due to its superior efficacy, safety, and broad applicability. Unlike live-attenuated vaccines, it is a recombinant, adjuvanted vaccine that provides over 90% protection even in adults over 70 and immunocompromised individuals. Its strong and durable immune response reduces the risk of shingles and postherpetic neuralgia, driving high physician and patient preference.

Extensive clinical evidence, global regulatory approvals, and robust marketing support by GSK further reinforce its leadership. Convenience, trust, and proven outcomes make Shingrix the preferred choice across private and public healthcare sectors, securing its overwhelming market share globally.

By Distribution Channel Insights

Hospitals lead the shingles vaccine market because they provide the most reliable and accessible setting for adult immunization, particularly for older and high-risk patients. They have trained medical staff to administer vaccines safely, monitor adverse reactions, and ensure proper storage and handling, which is critical for temperature-sensitive recombinant vaccines like Shingrix.

Large hospital networks, especially in North America and Europe, facilitate bulk procurement and consistent supply, supporting high-volume vaccination programs. Additionally, hospitals integrate vaccination into routine patient visits, increasing compliance and completion rates. These factors collectively position hospitals as the dominant and trusted distribution channel globally.

North America Shingles Vaccine Market Analysis

North America remains the dominant region in the shingles vaccine market, driven by strong awareness of herpes zoster, high healthcare spending, and widespread adoption of adult immunization programs. The area benefits from robust access to recombinant vaccines, such as Shingrix, supported by large hospital networks and retail pharmacy chains that streamline vaccination delivery.

In the U.S., demand is particularly strong due to CDC recommendations for adults aged 50 and above and expanded guidelines for immunocompromised individuals. High insurance coverage, strong physician advocacy, and extensive public-health campaigns further accelerate uptake. Growing emphasis on preventing postherpetic neuralgia and increasing aging populations continue to make North America the most influential growth hub for shingles vaccination.

Asia Pacific Shingles Vaccine Market Insights

Asia Pacific shingles vaccine market is expanding rapidly due to rising aging populations, increasing burden of chronic diseases, and improving awareness of herpes zoster prevention. Countries such as Japan, China, South Korea, and Australia are driving adoption, supported by the growing availability of recombinant vaccines and strengthening adult immunization policies.

Local manufacturers, including SK Bioscience with Sky Zoster, are enhancing regional competition and accessibility. Expanding private healthcare infrastructure and higher out-of-pocket spending are further boosting vaccine uptake, especially in urban areas. As governments integrate shingles prevention into healthy-aging initiatives, the Asia Pacific is emerging as one of the fastest-growing markets globally.

The shingles vaccine market is characterized by moderate competition, driven primarily by advancements in recombinant vaccine technology and growing global demand for immunization.

Recombinant vaccines hold the largest share due to their superior efficacy, durability, and suitability for older and immunocompromised adults, creating a strong competitive advantage over traditional live-attenuated options. Regional manufacturers continue to strengthen market presence through locally produced vaccines and expanding distribution networks.

Key Industry Developments:

• In July 2025, GSK plc received the US Food and Drug Administration (FDA) approval for a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster). The new prefilled syringe removed the need to reconstitute separate vials prior to administration, simplifying the vaccination process for healthcare professionals.
• In April 2023, GlaxoSmithKline Pharmaceuticals Ltd launched Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in India for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above. Shingrix became the world’s first non-live, recombinant subunit vaccine administered intramuscularly in two doses. Shingles was caused by the reactivation of the varicella zoster virus (VZV), the same virus responsible for chickenpox.